Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
New regimens, including combinations with chemical drugs, need to be studied to enhance the therapeutic efficacy of CAR-T or NK cells for solid tumors.
|
30410941 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors.
|
30678555 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Effective deployment of CAR T-cell immunotherapy for solid tumors has proven challenging to date, due to a series of formidable hurdles.
|
31038366 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we demonstrate an approach to enhancing CAR-T function in solid tumors by directly vaccine-boosting donor cells through their chimeric receptor in vivo.
|
31296767 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a promising strategy.
|
29423418 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Whereas much of the early success with CAR-T cells has been demonstrated with hematological malignancies, important barriers remain for the application of CAR-T cell therapies for the management of metastatic solid tumors.
|
27910858 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The data confirmed the antitumor ability and safety of CAR-T cells targeting EpCAM and may provide a new target for CAR-T cell therapies in treating solid tumors.
|
30693795 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Many potential targets for CAR-T cells in solid tumors are expressed in some normal tissues, raising concern for off-tumor toxicity.
|
30889382 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There are obvious differences between the two countries in CAR-targeted antigens in solid tumors and genetic modifications besides CARs for enhancing the potency of CAR T-cells.
|
30307029 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, due to the lack of ideal tumor surface antigens, CAR-T cell therapy has limited success in treating solid tumors.
|
31597088 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overall, our data document the superiority of local production of PD-L1 mini-body by CAd-VEC<i>PDL1</i> combined with administration of tumor-directed CAR T cells to control the growth of solid tumors.<i></i>.
|
28235763 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD56-CAR-T cell therapy is a safe and effective approach and may be an option for children with solid tumors who are nonresponsive to conventional radiotherapy and chemotherapy, or are unsuitable for hematopoietic stem cell transplantation.
|
31651858 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Amph-Ligand Vaccine Enhances CAR-T Cell Activity against Solid Tumors.
|
31324609 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We, herein, comment on the most salient aspects of CAR-T cell design and clinical experience in the treatment of solid tumors.
|
29203440 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors.
|
31754328 |
2019 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These works confirmed that simultaneous use of cytokines, for example, rhIL-12, can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors.
|
31237116 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, we will discuss extrinsic factors that can be manipulated to influence CAR-T performance such as choice of cellular population, culturing conditions and additional modifications that enhance their activity particularly in solid tumors.
|
26797495 |
2016 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
|
31707682 |
2020 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, these devices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against the emergence of escape variants.
|
28436934 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we provide our perspective on how to improve the success of CAR T therapy in solid tumors by focusing on the aspects of target selection and the related TME in CAR T cell design, especially stressing the interplay between them.
|
30906625 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Two preclinical studies indicate the potential of using biodegradable nanoparticles to program circulating T cells into CAR T cells <i>in situ</i>, and delivering these therapeutic cells directly to solid tumors via small dissolvable sponges.
|
28500027 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, CAR-T cell therapy has shown limited efficacy for the treatment of solid tumors.
|
31142602 |
2019 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines.
|
29634393 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors.
|
30636882 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These adjuvant-like effects of GSK3 inhibition on activated CAR-T cells may be a valuable adjunct to a successful implementation of CAR-T immunotherapy against GBM and other solid tumors.
|
29959057 |
2018 |